2002 IDSA Guidelines for a Cancer Patient with Neutropenia Who Is Afebrile After Initial Empiric Antibiotic Therapy

Description

A cancer patient with febrile neutropenia is evaluated after the first 3 to 5 days of empiric therapy. If the patient is afebrile then further therapy can be adjusted or discontinued. The authors are from the Infectious Diseases Society of America (IDSA) and multiple hospitals in the North America and Europe.

Patient selection: afebrile after first 3 to 5 days of therapy

Parameters:

(1) etiology of infection identified

(2) initial risk status

(3) age of the patient

Etiology	Initial Risk Status	Age of the Patient	Management
unknown	low	adult	ciprofloxacin and amoxicillin/ clavulanate
unknown	low	pediatric	cefixime
unknown	high	NA	continue previous regimen
identified	NA	NA	optimize regimen for agent

A patient who is low risk and afebrile can be discharged on oral medications in most cases.

To read more or access our algorithms and calculators, please log in or register.

2002 IDSA Guidelines for a Cancer Patient with Neutropenia Who Is Afebrile After Initial Empiric Antibiotic Therapy

Description

Specialty